Showing results (1891-1900 of 2,112) with videos related to
Sort By:
Pageof 212
Neuro-Oncology Advances|February 27, 2026
A Cre-mediated copy number variant compromises the reliability of a <i>LoxP-STOP-LoxP</i>-<i>PLAG1</i> driven brain tumor modelJan Vaillant, Sangita Pal, Jan Müller, et al.Frontiers in Microbiology|January 9, 2019
Iron Regulation in <i>Clostridioides difficile</i>Mareike Berges, Annika-Marisa Michel, Christian Lassek, et al.Journal of the American Chemical Society|July 7, 2026
Alternating Magnetic Field Promotes Ammonia Cracking by Disrupting the Sabatier Limitation of Ruthenium Catalytic SpeciesAlexander Adogwa, Hajar Hosseini, Abby Gardner, et al.Neuro-Oncology|February 11, 2026
The prognostic impact of CDKN2A/B hemizygous deletions in meningiomaFranziska M Ippen, Thomas Hielscher, Areeba Patel, et al.Research Square|February 24, 2025
Air sampling accurately captures circulating zoonotic viral diversity emerging from poultry live-animal marketsPeter Cronin, Jurre Siegers, Vireak Heang, et al.Acta Neuropathologica Communications|February 4, 2021
Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activationAndrey Korshunov, Konstantin Okonechnikov, Felix Schmitt-Hoffner, et al.NPJ Precision Oncology|April 18, 2026
GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapyCem M Sievers, Tian-Gen Chang, Yvette Robbins, et al.Journal of Clinical Medicine|December 11, 2025
Concomitant Surgical Ablation Using a Novel Bipolar Radiofrequency Clamp: Outcomes from the TRAC-AF RegistryChristian Shults, Armin Kiankhooy, Shaf B Holden, et al.Nature Communications|June 13, 2026
Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancerCem Sievers, Yvette Robbins, Marco Craveiro, et al.Leukemia|August 30, 2002
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)R A Larson, M Boogaerts, E Estey, et al.Pageof 212